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Abstract
NK and cd T cells can eliminate tumor cells in many experimental models, but their effect on the development of tumors
caused by virus infections in vivo is not known. Polyomavirus (PyV) induces tumors in neonatally infected mice of
susceptible strains and in adult mice with certain immune deficiencies, and CD8+ ab T cells are regarded as the main
effectors in anti-tumor immunity. Here we report that adult TCRb knockout (KO) mice that lack ab but have cd T cells remain
tumor-free after PyV infection, whereas TCRb6d KO mice that lack all T cells develop tumors. In addition, E26 mice, which
lack NK and T cells, develop the tumors earlier than TCRb6d KO mice. These observations implicate cd T and NK cells in the
resistance to PyV-induced tumors. Cell lines established from PyV-induced tumors activate NK and cd T cells both in culture
and in vivo and express Rae-1, an NKG2D ligand. Moreover, these PyV tumor cells are killed by NK cells in vitro, and this
cytotoxicity is prevented by treatment with NKG2D-blocking antibodies. Our findings demonstrate a protective role for NK
and cd T cells against naturally occurring virus-induced tumors and suggest the involvement of NKG2D-mediated
mechanisms.
Citation: Mishra R, Chen AT, Welsh RM, Szomolanyi-Tsuda E (2010) NK Cells and cd T Cells Mediate Resistance to Polyomavirus–Induced Tumors. PLoS
Pathog 6(5): e1000924. doi:10.1371/journal.ppat.1000924
Editor: Michael J. Imperiale, University of Michigan, United States of America
Received January 31, 2010; Accepted April 26, 2010; Published May 27, 2010
Copyright:  2010 Mishra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institute of Health Grants CA 66644 and CA 34461. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Eva.Szomolanyi-Tsuda@umassmed.edu
Introduction
Virus-induced tumors mostly develop in immune-compromised
hosts, suggesting that the immune system provides protection
against the induction and/or progression of these tumors. T cells
expressing a and b TCR and recognizing viral peptide epitopes
are thought to be important for this protection. However, other
cell types of the immune system, including NK cells and cd T cells,
are also endowed with effector functions similar to those of ab T
cells, but their role in the control of virus-induced tumors is largely
unexplored.
A growing body of experimental evidence suggests that tumor
cells can be recognized and eliminated by NK cells and cd T cells.
In a variety of human cancers such as lung, colon and renal cell
carcinomas NK cells and cd T cells can be found among tumor
infiltrating lymphocytes (TIL) [1,2,3,4]. Moreover, NK cell
infiltration of tumors was noted to be associated with improved
prognosis in some human cancers [4,5,6]. Implanted syngeneic
tumors, including those induced by tumor viruses, grow more
aggressively in mice if no functional NK cells are present [7]. cd T
cells can also protect mice against transplanted hematopoietic
tumors [8], and mice deficient in cd T cells have an increased
susceptibility to chemically induced cutaneous tumor formation
[9]. Acute virus infections, as well as other NK cell activating
agents, can augment the rejection of implanted tumor cells [7].
Nevertheless, evidence that NK and cd T cells can control the
formation and progression of naturally occurring virus-induced
tumors is lacking.
Polyomavirus (PyV), a small DNA tumor virus that carries
potent oncogenes, can transform a variety of cells in culture
readily, but infection of adult immune competent mice (the natural
host for PyV) does not lead to tumor formation. However, PyV
infection causes a wide variety of tumors affecting multiple tissues
and cell types when neonatal mice of some ‘‘susceptible’’ mouse
strains are infected, and it also causes tumors in adult mice with
certain immune-deficiencies [10,11]. Neonatal mice of the tumor
susceptible mouse strains rapidly gain resistance after birth, and
become refractory to tumor induction by the virus within a few
days. The importance of the immune system in tumor resistance is
indicated by observations that mouse strains highly resistant to
PyV-induced tumor formation could be rendered tumor suscep-
tible with immune suppressive treatments such as neonatal
thymectomy, irradiation, and administration of anti-lymphocyte
serum [12,13,14].
A high level of virus replication and spread seems to be a
prerequisite for PyV-induced tumor development. Therefore,
antiviral immune responses which decrease the virus load and
reduce the levels of virus persistence may also decrease the chances
of tumor formation. This does not mean, however, that antiviral
resistance is always coupled with resistance against tumors and
vice versa. For example, antibody responses to PyV reduce the
virus load, but they do not prevent tumor formation [15]. CD8 T
cells specific for PyV viral peptides, on the other hand, reduce
virus load and also have a role in preventing the formation of
virus-induced tumors [16,17,18]. Endogenous super-antigens
encoded by a mouse mammary tumor provirus Mtv-7 have been
shown to increase susceptibility of neonatal mice to PyV-induced
tumors by eliminating Vb6+ T cells from their T cell repertoire;
Vb6T cells make up the majority of the CTLs reactive to the
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that in the rejection of PyV-induced tumor cells transferred into
PyV-immune mice both CD4 and CD8 ab T cells were shown to
play a role [20]. Consistent with the role of ab T cells mediating
tumor resistance, athymic nude mice infected as adults developed
tumors, as did mice lacking b2m, an essential component of MHC
class I molecules [17]. However, it is possible that there is a
redundancy in antitumor responses and that CD8 T cells specific
for viral peptides do not act only by themselves against the PyV-
transformed tumor cells. The contribution of various other cell
types capable of cytotoxic activity, such as cd T cells or NK cells to
PyV tumor resistance in vivo has not been investigated so far.
Here we report that cd T and NK cells can prevent tumor
formation in PyV-infected ab T cell-deficient mice. PyV-induced
tumor cell lines activate cd T cells and NK cells in vitro and in
vivo. Moreover, these tumor cell lines express Rae-1 ligands
recognized by NKG2D, an activating receptor expressed on all
NK cells and some cd T cells, they are efficiently killed by NK cells
in vitro and this killing is NKG2D-mediated. These data taken
together show a major role for cd T cells and NK cells in tumor
resistance in a naturally occurring virus-induced tumor model,
implicate NKG2D-NKG2D ligand interactions in these antitumor
responses, and suggest that ab T cells, cd T cells and NK cells may
work together to prevent tumor formation during life-long virus
persistence.
Results
PyV infection induces a high incidence of tumor
development in TCRb6d KO and E26 (T and NK cell-
deficient), but not in TCRb KO mice
In order to understand which components of the immune
system are required to control PyV -induced tumor formation in
adult mice we tested the outcome of long-term PyV infection in
TCRb KO mice that lack ab T cells, TCRb6d KO mice that lack
all ab and cd T cells, and E26 mice that lack all T cells and NK
cells [21]. Following intranasal infection with 2610
6 p.f.u. of PyV
strain A2 (‘‘high tumor’’ strain) ,80% of TCRb KO mice
survived for ten months and all of them were free of tumors,
whereas only 1 out of 20 (5%) TCRb6d KO mouse was alive at
this time point and ,60% of the TCRb6d KO mice had
developed large tumors (Fig. 1A and B). The tumors were detected
by visual observation and palpation, usually when their size
exceeded ,0.5 cm in diameter. The TCRb6d KO mice which
died but are not counted as tumor bearing had hind leg paralysis, a
condition seen in many previous studies [22,23] and likely due to
bone tumors of the spine or possibly other PyV-induced
neurological conditions, or died of unknown causes. The tumors
found by gross examination were almost all salivary gland tumors,
often occurring bilaterally. The lack of a wide spectrum of tumors
in these mice is similar to findings previously reported for B6/b2m
KO mice infected as adults [22]. Similar results were obtained
with mice infected intraperitoneally (i.p.). For example, in a more
limited study, 0/8 TCRb6d KO mice, 4/5 TCRb KO mice and
10/10 B6 mice were alive and tumor-free at 5 months post
infection when PyV was given i.p. There was an earlier
appearance of tumors in E26 mice than in TCRb6d KO mice
(Fig. 1C), suggesting that NK cells may also contribute to tumor
resistance and delay the onset of tumor formation.
PyV load is not different in organs of TCRb KO and
TCRb6d KO mice
NK cells and cd T cells may provide protection against PyV-
induced tumors by directly eliminating the emerging tumor cells,
or indirectly, by lowering the PyV titer in various organs and
thereby decreasing the chances of cell transformation and tumor
development. To test the effect of cd T cells on viral load we
compared the number of PyV genome copies in the salivary glands
and lungs of TCRb KO and TCRb6d KO mice at various time
points after intranasal PyV infection, but before tumors were
detectable in TCRb6d KO mice. The number of viral genome
copies on days 3, 6, 12 and 15 (Fig. 2A and B; short-term infection)
and on days 75, 90 and 100 (Fig. 2C and D; long-term infection),
were not significantly different in the lungs or salivary glands
between TCRb KO and TCRb6d KO mice. This observation
suggests that the cd T cells provide protection against PyV-
induced tumors by controlling tumor development, rather than by
reducing viral load in the target organs prior to PyV-induced
tumor formation. Previous studies in our lab showed that in vivo
NK cell depletion did not increase PyV titers in the kidneys and
spleens of SCID mice one week after PyV infection i.p., suggesting
that NK cells did not have a direct role in the control of PyV levels
in those organs at the acute phase of the infection [24].
PyV-induced salivary gland tumor cell lines express the
NKG2D ligand Rae-1
NK cells and cd T cells may recognize PyV-induced tumor cells
by detecting tumor cell antigens on their surface via activating
receptors, such as NKG2D. We established several cell lines from
salivary gland tumors isolated from PyV-infected TCRb6d KO
mice and tested them for the expression of the NKG2D ligands
Rae-1, H60 and MULT1. These cell lines, PyVTu1, PyVTu2 and
PyVTu3, were all positive for Rae-1, H60 and MULT1 transcripts
by reverse transcriptase (RT) PCR (Fig. 3A). The Rae-1 specific
primers could amplify cDNA reverse transcribed from mRNA of
all Rae-1 family members, a, b, c, d and e, and gave the same size
PCR product. We also tested the expression of NKG2D ligand
surface proteins on PyVTu cells by staining them with monoclonal
antibodies against Rae-1, H60 and MULT1. All of the cell lines
tested, PyVTu1, PyVTu2 and PyVTu3, had a high expression of
Rae-1 but H60 or MULT1 surface protein expression was not
detectable on these cell lines despite the abundant H60 and
Author Summary
Virus-induced tumors account for a large fraction of
malignancies in both humans and mice. These tumors
express viral antigens and have been thought to be
controlled mostly by ab TCR+ CD8 T lymphocytes that are
specific for viral peptides. We found that mice lacking ab T
cells are protected from the formation of tumors induced
by the small DNA virus polyoma (PyV) if they have cd T and
NK cells. Moreover, cell lines we established from the virus-
induced tumors induced NK and cd T cell activation, and
expressed Rae-1, a cellular stress molecule which serves as
ligand for NKG2D, an activating receptor on NK and cd T
cells. NK and cd T cells seemed to mount antitumor but
not antiviral responses, as their presence did not change
the amount of persisting virus significantly. Our studies
suggest that mice have a multipronged host defense
against PyV-induced tumors that includes cd T and NK cells
in addition to ab T cell responses. Merkel cell virus, a tumor
causing polyomavirus in humans, is closely related to PyV
with a similar biology, making it very important to
understand mechanisms involved in host control of tumor
development in the course of these life-long persistent
infections.
NK and cd T Cells in PyV Tumor Resistance
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expressed Rae-1, H60 and MULT1 messages and surface
proteins, whereas RMA T cell lymphoma cells did not express
Rae-1, H60, only low levels of MULT1 mRNA, and none of these
surface proteins, and served as negative controls. NK cells can also
detect the expression of class I MHC molecules on their targets
and preferentially kill cells displaying low levels of class I MHC
molecules. However, we found that PyVTu cells express high
levels of class I MHC molecules, unlike YAC-1 cells which have
low levels of class I expression (Fig. 3B).
PyVTu cells activate NK cells and cd T cells in-vitro and in-
vivo
To test the ability of PyVTu cells to activate NK cells and cd T
cells in vitro, spleen cells of uninfected TCRb KO mice were
incubated with PyVTu cells with or without PMA and ionomycin
treatment, followed by intracellular cytokine staining for IFNc and
granzyme-B. PMA and ionomycin are commonly used for non-
specific stimulation of cytokine production in various cell types and
they were also reported to increase the IFNc mRNA half-life in
activated NK cells [25]. The PyVTu cells were incubated with
spleen leukocytes at a ratio of 10:1. Spleen cells from TCRb KO
mice were used in these experiments, because they contain a
higher percentage of cd T cells than do spleens of B6 mice. The
addition of PyVTu cells and PMA and ionomycin treatment
together resulted in a significant increase in the percentage of
IFNc producing NK cells and cd T cells and also a major increase
in the mean fluorescent intensity (MFI) of intracellular IFNc
staining in these cells compared to NK and cd T cells only treated
with PMA and ionomycin (Fig. 4A, B and C), suggesting that
PyVTu cells played an important role in NK and cd T cell
activation. Incubation of NK cells and cd T cells with PyVTu cells
also led to increased granzyme-B production in these cell types
compared to cultures without PyVTu cells, even in the absence
additional PMA and ionomycin stimulation (Fig. 4D, E and F).
The increase in granzyme-B production by cd T cells following
their co-culture with PyVTu cells was small, but reproducible, a
consistent observation in multiple experiments.
We also tested whether PyVTu cells activate NK cells and cd T
cells in vivo. PyVTu cells were injected i.p. into TCRb KO mice
(5610
6 cells/ mouse), and 3 days later peritoneal exudate cells
(PEC) were harvested and incubated for 4 hours with or without
PMA and ionomycin stimulation, and tested for IFNc and
granzyme-B production by intracellular cytokine staining. There
Figure 1. Survival and tumor incidence of PyV-infected TCRb KO, TCRb6d KO and E26 mice. (A) Survival of TCRb KO and TCRb6d KO mice
after PyV (2610
6 p.f.u., i.n.) infection. (B) Tumor incidence in TCRb KO and TCRb6d KO mice in the same experiment. N=20 mice per group. (C) Tumor
incidence in E26 mice that lack both NK and T cells and in TCRb6d KO mice after PyV (2610
6 p.f.u., i.p.) infection. N=15 mice per group. One
representative of at least two similar independent experiments is shown.
doi:10.1371/journal.ppat.1000924.g001
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population after injection of tumor cell lines. In one representative
experiment 3 days after PyVTu cell injection there were 22.3%
NK1.1+/ CD32 cells in the peritoneum, whereas control mice
that did not receive PyVTu cells had approximately 3.8% NK cells
(Fig. 5A). The total number of PEC recovered from mice three
days after PyVTu cell injection was 7–10 times higher than that
from untreated mice, and the number of NK cells in PyVTu-
injected mice was ,46 times higher than in untreated mice
(Fig. 5A). The percentage of cd T cells did not change after
PyVTu cell injection, but the number of cd T cells in the
peritoneum of PyVTu–injected mice was ,8 times higher than in
the untreated controls (Fig. 5A).
NK cells from the PEC of PyVTu cell-injected mice had
increased IFNc production compared to untreated mice, a higher
percentage of cells was IFNc+, and the IFNc staining had a higher
MFI. This difference was also consistent, but smaller in magnitude
in the absence of ex vivo PMA and ionomycin stimulation.
However, cd T cells in the PEC did not have similar increases in
IFNc production after PyVTu cell injection (Fig. 5B, C and D). In
the same experiments both NK cells and cd T cells from PEC had
increased granzyme-B production after PyVTu cell injection i.p.
compared to untreated mice, and this was manifested by higher
percentages of granzyme-B positive NK and cd T cells and higher
MFI of granzyme-B staining for NK cells (Fig. 5E, F and G). The
IFNc production was greatly stimulated by a brief in vitro PMA
and ionomycin treatment, but granzyme-B production did not
require any stimulation in vitro. I.p. injection of RMA cells into
mice did not result in an increase in peritoneal NK cells and NK
or cd T cell activation, as judged by intracellular IFNc and
granzyme-B staining (see Fig. S1A and B). This result indicates
that the ability to activate NK cells and cd T cells in the peritoneal
cavity is somewhat selective for PyVTu cells, and it does not occur
in response to injection of any murine tumor cell line.
CD107a and CD107b (LAMP1 and LAMP2) is expressed on
the surface of NK cells and CD8 T cells as they undergo
activation-induced degranulation, and these markers can be used
as a direct measure of the cytotoxic potential of these cells [26].
There was a significant increase in CD107a and CD107b
expression on NK cells from PEC of mice injected i.p. with
PyVTu cells in comparison to the NK cells from untreated mice
(Fig. 6). This result is consistent with our other findings and gives
additional support for the notion that PyVTu cells induce
cytolytically active NK cells in vivo. Similar experiments
performed with cd T cells did not indicate CD107a or CD107b
up-regulation.
PyVTu cell lines harbor a high number of PyV DNA genomes
(5610
8 copies/mg of cell DNA) and also shed some infectious virus
Figure 2. Viral load in organs of TCRb KO and TCRb6d KO mice at different time points after in PyV infection. The viral load was
determined by qPCR measuring PyV genome copies per mg of organ DNA in samples isolated from salivary glands (A, C) and lungs (B, D) at various
time points during acute (A, B) and long-term persistent infection (C, D). N=3 in (A) and (B), N=5 in (C) and (D). Open squares: TCRb6d KO mice,
closed diamonds: TCRb KO mice, mean +/2 s.d. One representative of three independent experiments is shown.
doi:10.1371/journal.ppat.1000924.g002
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cells and cd T cells by PyVTu cells in vivo could be merely due to
the released infectious virions. Several lines of experimental
evidence suggest that this was not the case. First, i.p. infection of
mice with 2610
6 p.f.u. of PyV (a virus dose several orders of
magnitude higher than the amount of virus which would be shed
by injected PyVTu cells) did not result in increases of PEC, NK or
cd T cell percentages or numbers comparable to the ones observed
after injection of PyVTu cells (Fig. S2A). Second, PyV infection
i.p. activated NK and cd T cells to produce IFNc as did PyVTu
injection (Fig. S2B), but in contrast to PyVTu cells, the viral
infection did not lead to high levels of granzyme-B production (Fig.
S2C). Based on these findings we reason that the activation and
expansion of NK and cd T cells by PyVTu cells could not be
merely due to infectious virus release by PyVTu cells.
NK cells kill PyVTu cells by a NKG2D-dependent
mechanism
NK cells are thought to exert a potent antitumor activity by
directly killing tumor cells. We tested the ability of in vivo activated
NK cells to kill PyVTu cells in vitro in chromium release
cytotoxicity assays. PyVTu and YAC-1 cell targets were efficiently
killed by PEC effectors taken from TCRb KO mice injected with
PyVTu cells three days prior to the PEC harvest. This killing was
completely abolished, however, when the PEC was taken from
PyVTu-injected, NK cell-depleted mice (Fig. 7A). These results
demonstrated that PyVTu cells are sensitive to activated NK cell-
mediated killing. NK cells enriched from spleens of untreated
SCID mice by MACS separation likewise killed PyVTu targets,
and importantly, this killing was completely prevented by
treatment with an NKG2D blocking monoclonal antibody CX5,
Figure 3. Expression of NKG2D ligands on cell lines established from PyV-induced salivary gland tumors of TCRb6d KO mice. (A) RT-
PCR detection of Rae-1, H60, Mult1 and b-actin transcripts in three salivary gland tumor cells lines established from PyV-induced tumors that
developed in TCRb6d KO mice (PyVTu1, PyVTu2 and PyVTu3), and in YAC-1, RMA and MC57G cell lines. The expression of message for b-actin in the
same samples is shown at the bottom panel. (B) Expression of Rae-1, H60, Mult1 and MHC class I proteins on the surface of PyVTu1, PyVTu2 and
PyVTu3 cell lines, and also on YAC-1, RMA and MC57G cells. Grey shaded area: staining with isotype controls, open red lines: Rae-1, H60, Mult1 or
MHC I-specific antibody staining. The experiment was repeated two (for H60, MHC I) or more (for Rae-1) times with similar results.
doi:10.1371/journal.ppat.1000924.g003
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C). Experiments with another NKG2D-specific blocking mono-
clonal antibody, MI6, gave similar results (data not shown). NK
cell-mediated killing of RMA cell targets, on the other hand, was
not prevented by CX5 treatment. RMA cells do not express
known NKG2D ligands, and therefore they may be recognized
and killed by activated NK cells by NKG2D-NKG2D ligand-
independent mechanisms (Fig. 8A and B). From these studies we
conclude that the interaction of the activating receptor NKG2D
on NK cells with NKG2D ligands, such as Rae-1 expressed on
PyVTu cells was essential for the NK cell-mediated killing of these
virus-induced tumor cells.
Discussion
In this report for the first time we provide evidence for the
critical role of cd T cells and NK cells in mice in the resistance to
naturally occurring virus-induced tumors. Following infection with
PyV, a natural mouse pathogen with strong oncogenic potential,
mice that lacked ab T cells, but had cd T cells, remained tumor
free, but mice lacking both ab and cd T cells developed tumors by
six months post infection. An additional role for NK cells was
suggested by an earlier onset of tumor formation in mice lacking
both NK and T cells in comparison to T cell-deficient mice that
have NK cells.
An increasing body of data obtained in both mice and humans
suggests that cd T cells may constitute an important component of
the immunological resistance to tumors, although direct evidence
showing that they control tumors induced by viral infections in
vivo has been lacking so far. cd T cells were found among tumor
infiltrating lymphocytes (TIL) in human tumors such as lung
cancer, colon carcinomas and renal cell carcinomas [1,2,3,27,28].
Moreover, cd T cell clones established from TIL or PBMC of
cancer patients could kill autologous tumors in vitro in cytotoxicity
assays [27,29,30,31], and the growth of human melanoma cells
engrafted on SCID mice was inhibited by transfusion of Vd1 cd T
cells and NK cells from the same patient [32]. Mice deficient in cd
T cells have been shown to have increased susceptibility to
chemically induced cutaneous tumors [9], but their role in
resistance to natural virus-induced tumor formation had never
been demonstrated.
NK cells preferentially kill cells with low MHC class I
expression, and tumor cells often down-regulate class I expression
to escape from CD8+ T cell responses [33]. Therefore, tumor cell
killing was postulated decades ago to be a major function for NK
cells [7]. Indeed, low NK cell-mediated cytotoxicity of PBMC
correlates with increased risk of tumor development in people
[34]. Moreover, NK cell infiltration of tumors is associated with a
better prognosis in a variety of carcinomas [4,5,6], and transfer of
alloreactive NK cells increases the survival of patients with
leukemia [35]. Implanted syngeneic tumors grow more aggres-
sively in mice if no functional NK cells are present. Administration
of cytokines known to enhance NK cell function can lead to
accelerated elimination of implanted tumors [7]. The role of NK
and cd T cells in the control of naturally occurring or spontaneous
tumors, however, has been less understood. Here we show data
indicating a major role for both cd T cells and NK cells in tumor
immunity in a natural model of tumors induced by virus infection.
NKG2D is a molecule known to be involved in target
recognition of both cd T cells and NK cells [36], it is a type II
trans-membrane glycoprotein with a C-type lectin binding
domain, expressed as a disulfide-linked homodimer. Its ligands,
Rae-1 (a–e), H60 and Mult-1 in mice, are regarded as markers of
cell stress [37,38]. Here we demonstrate that cell lines established
from PyV-induced tumors express Rae-1. These cells activate NK
and cd T cells in vitro and in vivo, and NK cells kill these tumor
cells in vitro in an NKG2D-dependent fashion. These findings
suggest that cd T cells and NK cells may recognize emerging PyV-
transformed cells expressing Rae-1 stress molecules by their
NKG2D receptors. NKG2D is a major activating receptor on NK
cells, although NK cell activation is influenced by a variety of
other receptors as well. The signals received from NKG2D are
transmitted via DAP10, and in mice also the DAP12 signaling
molecules [36,39,40,41]. cd TCR and NKG2D are both major
sources of activating signals on cd T cells. Whether the cd TCRs
get any stimulation from from PyV-induced tumors is an open
question.
Freshly isolated cd T cells lack in vitro cytolytic activity in most
studies, and there are only a few reports on in vitro cytotoxic
activity using target cells infected by pathogens [42]. In contrast to
the easily demonstratable cytotoxic activity mediated by NK cells,
we could not demonstrate in vitro killing of PyVTu cells by cd T
cells in this study. Nevertheless, the tumor resistance of TCRb KO
and susceptibility of TCRb6d KO mice strongly argues for the
involvement of some cd T cell effector mechanisms in the
antitumor responses in vivo.
A variety of virus-infected cells also express Rae-1 and other
stress molecules recognized by NKG2D. Examples for the viruses
which induce these stress molecules are HCMV, MCMV,
influenza A and Epstein Barr Virus [43]. Acutely PyV-infected
TCRb KO mice on day 7 post infection, however, did not show
an increase in Rae-1 transcripts in spleen and salivary gland tissues
(Fig. S3A). Moreover, in SCID mice on day 6 post infection, when
spleens have a high PyV load, macrophages and DC, cell types
known to be infected with PyV, did not up-regulate Rae-1
expression (data not shown). Therefore PyV infection of these cells
in vivo does not seem to induce Rae-1 expression on their surface.
In vitro infection of NIH 3T3, UC1b and MC57G cells with PyV
does not change their expression of Rae-1 protein, and only in
primary mouse embryonic fibroblast (MEF) cultures was an
increase in Rae-1 expression seen after PyV infection (Fig. S3B).
Killing of PyVTu cells by activated NK cells in vitro was
prevented by NKG2D blocking antibodies, showing that
NKG2D-dependent mechanisms play an essential role in NK
cell-mediated cytotoxic responses to PyVTu cells. These findings
suggest that cd T cells and NK cells may control the outgrowth of
Figure 4. Activation of NK cells and cd T cells by co-culture with PyVTu cells in vitro. (A) Flow cytometry of intracellular IFNc staining of
spleen cells cultured with or without PyVTu cells and/or PMA and ionomycin stimulation, gated on NK cells (NK1.1+CD32) and (B) on cd T cells (cd
TCR+CD3+). The numbers indicate the percentage of IFNc+ NK or cd T cells, respectively. (C) Percentages of IFNc+ NK and cd T cells and mean
fluorescent intensity (MFI) of the IFNc staining obtained with cultured spleen leukocytes from three individual mice are summarized, mean +/2 s.d.
values are shown. The filled bars indicate cultures without PyVTu cells and stimulation, the open bars with PyVTu cells, but without stimulation, the
bars with horizontal stripes without PyVTu cells, but with stimulation and the bars with vertical stripes with PyVTu cells and PMA and ionomycin
stimulation. The asterisks indicate statistically significant (P,0.05) differences determined by student’s t test. (D) Intracellular granzyme-B (Grz-B)
staining gated on NK cells and (E) cd T cells in the same experiment. (F) Percentages of granzyme-B+ NK and cd T cells and MFI of staining. Mean and
s.d. of three cultures is shown, the bars are as described for (C). The asterisks indicate statistically significant (P,0.05) differences. The experiments
shown were repeated at least twice with similar results.
doi:10.1371/journal.ppat.1000924.g004
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permissively infected cells by the same mechanisms. This scenario
is supported by our findings that TCRb KO and TCRb6d KO
mice did not differ in viral load at various time points post PyV
infection. Thus, cd T cells do not have a significant effect on the
control of PyV levels in vivo. Of note is that the titers of T cell-
independent antiviral IgG responses are not significantly different
in PyV-infected TCRb KO and TCRb6d KO mice, therefore cd
T cells do not contribute as helper cells enhancing antiviral
humoral immunity either [44]. Previously we have also reported
that NK depletion did not lead to increased viral titers in various
organs of PyV-infected SCID mice [24], suggesting that NK cells
have no direct antiviral role in these animals. Thus, we conclude
that cd and NK cells seem to mount an antitumor, but not an
antiviral response in PyV-infected mice.
PyV can infect a variety of cell types and replicate in a broad
range of tissues in mice, and it also has a strong ability to transform
cells and induce tumors. Nevertheless, PyV-induced tumors are
rare in nature or in wild type adult mice. This suggests that the
immune system applies a very successful, multi-pronged strategy
against PyV-induced tumor formation. Persisting high virus levels
seem to be a prerequisite for tumor formation. Therefore the
control of viral spread and replication by B cells and ab T
lymphocytes decreases the likelihood of cell transformation and
the generation of tumors. Humoral immunity reduces the viral
levels even in the absence of T cell help [15], but B cell responses
by themselves do not prevent tumor formation, as TCRb6d KO
mice containing B cells develop tumors. CD8+ ab T cells act
against virus-infected cells and also against tumor cells expressing
viral epitopes [11]. A reduced population of middle T epitope-
specific Vb6+ CD8 ab T cells in H2k mice carrying Mtv-7
superantigens seems to correlate with increased tumor-suscepti-
bility of these mice when infected as neonates [19]. Our study now
shows for the first time, that when ab T cells are not functional,
NK cells and cd T cells can provide an additional potent line of
defense against virus-induced tumor development, by responses
that are not specific for viral-coded proteins, but instead probably
directed against tumor cell-expressed stress molecules.
The high tumor incidence observed in PyV-infected TCRb6d
KO mice that have NK cells brings up the question of why NK
cells cannot overcome tumor development in the absence of cd T
cells, and why NK cells only delay but don’t prevent tumor
formation. We speculate that this finding can be explained by the
concept of immune editing, which describes the interaction of
emerging tumors with the host immune system in three phases,
elimination, equilibrium and escape [45]. NK cell responses may
represent the first phase of immune editing, eliminating only a
fraction of the emerging tumors. The remaining tumor cells
eventually may overwhelm the NK cells, perhaps by escaping
recognition and/ or loss of NK functionality. This hypothetical
scenario is supported by our preliminary findings that large tumors
freshly isolated from TCRb6d KO mice although express Rae-1
mRNA, lack Rae-1 protein expression on the cell surface (R.
Mishra unpublished). Mice which have cd T cells in addition to
NK cells, however, have a numerical advantage of effector cells
against the emerging tumors. As a consequence, either all tumor
cells may be eradicated at the elimination phase, or if residual
tumor cells are left, they may be handled by a second wave of
effectors, which may sense and attack the tumor cells, perhaps by
another mechanism.
Figure 5. Activation of NK cells and cd T cells in vivo by i.p. injection of PyVTu cells. (A) Percentages (left panel) and numbers (right panel)
of peritoneal NK and cd T cells in TCR b KO mice 3 days after i.p. injection of PyVTu1 (5610
6/mouse) cells. PECs of three naive mice that did not
receive cells were pooled and analyzed in comparison, PECs from the PyVTu1 cell-injected mice were enumerated individually (n=3), mean and +/2
s.d. is shown. (B) Intracellular IFNc staining of PEC gated on NK cells and (C) cd T cells from untreated and PyVTu1 cell-injected TCRb KO mice from the
same experiment with or without PMA and ionomycin stimulation. The numbers indicate percentages of IFNc + cells. (D) Percentages of IFNc+ NK
and cd T cells and mean fluorescent intensity (MFI) of IFNc staining. Filled bars represent pooled sample from 3 naı ¨ve mice without stimulation, open
bars the mean + s.d. of samples from 3 PyVTu1-injected mice without stimulation, bars with horizontal stripes pooled samples from 3 naı ¨ve mice with
stimulation and bars with vertical stripes the mean +s.d. of samples from 3 PyVTu1-injected mice with stimulation. (E) Intracellular Grz-B staining of
NK and (F) cd T cells in the same experiment. (G) Percentage of Grz-B+ NK and cd T cells and mean fluorescent intensity (MFI) of staining. The bars are
as described for (D). The experiment shown is one representative of at least 3 independent experiments.
doi:10.1371/journal.ppat.1000924.g005
Figure 6. CD107 a/b staining of NK cells from PEC of TCRb KO mice injected with PyVTu1 cells in-vivo indicates cytotoxic potential.
PECs from 4 untreated (pooled) and from 3 i.p. PyVTu1 cell- injected TCRb KO mice were harvested three days after tumor cell injection and tested for
CD107a/b expression by flow cytometry. The cells were gated on NK1.1+ CD32 NK cells.
doi:10.1371/journal.ppat.1000924.g006
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has been known for decades that most people harbor polyoma-
viruses, such as BK and JC virus, which persist at low levels, but
are harmless in healthy individuals, similar to PyV in normal mice.
Patients with impaired immunity, however, suffer from severe
pathology associated with the reactivation of these viruses. New
human polyomaviruses have recently been identified [46], and one
of them is associated with the malignancy Merkel cell carcinoma.
This neuroepithelial cancer is rare, and develops mostly in
immune-compromised individuals. A large majority of the
population is seropositive for the Merkel cell carcinoma-associated
polyomavirus and may have a low level persistent infection. New
insights obtained in the mouse PyV model may, in addition
to elucidating general mechanisms of tumor control, also help
to understand and treat polyomavirus –associated human
malignancies.
Figure 7. NK cell kill PyVTu targets in a NKG2D-dependent manner. (A) PECs activated in vivo by i.p. injection of PyVTu cells two days prior
to harvest were used as effectors, and PyVTu1 and YAC-1 cells were used as target cells in an in vitro Cr release assay. The PECs were derived from
TCRb KO mice or from TCRb KO mice treated with anti-NK1.1antibodies (PECs-NK). (B and C) NK cells enriched from spleens of uninfected SCID mice
were used as effectors against PyVTu1 (B) and PyVTu2 (C) cell targets in the presence of NKG2D blocking (clone CX5) or isotype control antibodies.
doi:10.1371/journal.ppat.1000924.g007
Figure 8. NKG2D blocking antibodies prevent killing of PyVTu cells, but not RMA cells targets by activated NK cells in vitro. In vitro
cytotoxicity assays with activated PEC effector cells from TCRb KO mice and with PyVTu1 (A) and RMA (B) targets in the presence of no antibodies,
NKG2D blocking antibody or isotype control antibody. The PEC effectors were activated in vivo by i.p. injection of PyVTu cells two days prior their
harvest.
doi:10.1371/journal.ppat.1000924.g008
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Mice and infections
All the mice used in the studies were on the C57BL/6 (B6)
background. TCRb KO, TCRb6d KO and SCID mice were
obtained from the Jackson Laboratory (Bar Harbor, Maine), and
colonies of these mice were maintained in the Department of
Animal Medicine of the University of Massachusetts under specific
pathogen free conditions. E26 mice which express the human
CD3E transgene in high copy numbers and are defective in T cells
and NK cells [21] were originally obtained on the CBA/
J6C57BL/6 mixed background from the Jackson Laboratory,
and were fully back crossed onto the C57BL/6 background and
bred at the University of Massachusetts Medical School. Mice
were used between 8 and 12 wk of age, virus infections were done
i.n. or i.p. with 2610
6 PFU of PyV strain A2. All the procedures
using animals were done according to the protocols ‘‘Immunology
of virus infections’’ approved by the University of Massachusetts
Medical School Animal Care and Use Committee.
Quantitative PCR (qPCR) to measure viral DNA genome
copy number
DNA was prepared from organ homogenates by digestion with
proteinase K (Sigma) at 55uC overnight, followed by phenol
extraction and RNase-A treatment (10u/ml, Promega). The PCR
amplification was performed as described previously [47]. 50 ml
reaction mix containing 50 mM Tris pH 8.0, 0.5 mg/ml BSA,
3 mM MgCl2, 0.25 mM of each deoxynucleotide triphosphate,
0.5 U of Taq polymerase (Promega), 0.66 U SYBR-Green
(Molecular Probes), 0.1mM each of forward and reverse primer
(Invitrogen), 5nM Fluorescein (Bio-Rad) and 1 mg of the DNA
sample tested was used. The following primers were used: b actin
forward CGA GGC CCA GAG CAA GAG AG; b actin reverse
CGG TTG GCC TTA GGG TTC AG; PyV VP1 forward CCC
CCG GTA CAG GTT CAG TCC CAT CAT; VP1 reverse GGC
ACA ACA GCT CCA CCC GTC CTG CAG. The amplification
for VP1 started with one cycle at 95uC for 3 min, 37 cycles of
95uC for 30 sec, 65uC for 20 sec, 72uC for 45 sec. PCR
amplification with the b actin primers started with one cycle at
95uC for 150 sec, then 40 cycles of 95uC for 30 sec, 62uC for
25 sec, and 72uC for 25 sec. Negative controls included a sample
with no DNA substrate, and DNA from uninfected mouse organs.
Three-fold serial dilutions of DNA prepared from uninfected
mouse organs (spanning 1mg- 31 ng) were used to generate a
standard curve for b actin PCR. For PyV we used a recombinant
plasmid containing the VP1 coding sequences and made dilution
series from 2610
8 copies to 20 copies and mixed these plasmids
with 1 mg of DNA from uninfected mouse organs. All the reactions
were run in duplicates. The obtained PyV copy numbers were
normalized for b actin which reflected the amount of mouse
genomic DNA present, and the results were expressed as PyV
genome copies/ mg organ DNA.
Generation of PyV tumor cell lines
Salivary gland tumors were aseptically excised from euthanized
PyV-infected TCRb6d KO mice. The tumor tissues were rinsed
with sterile DMEM containing antibiotics and cut into small pieces
and digested with type I collagenase (100U/ml) in 10ml of DMEM
containing 10% FCS for 1 hr. The cells were then harvested and
plated in DMEM containing 10% FCS. Subsequently the
adherent cells were trypsinized and propagated through multiple
passages to obtain the transformed cell lines. The three salivary
gland tumor cell lines used in these studies, PyVTu1, PyVTu2 and
PyVTu3, were independently derived from three tumor bearing
TCRb6d KO mice. These cell lines have been propagated for
over 30 to 40 passages so far without showing major changes in
growth or survival.
Reverse transcriptase (RT) PCR and qRT PCR to detect
NKG2D ligand messages
RNA samples from various organs or cell lines were isolated by
Trizol (Invitrogen) or using the RNeasy mini kit (Qiagen) following
the manufacturer’s protocol. Two mg of total RNA from each
samples was used to synthesize 1st strand cDNA using 0.5mgo f
oligo dT (Invitrogen) and superscript II RT (Invitrogen) following
the manufacturer’s protocol. The PCR amplification was carried
out in a total volume of 50ml containing 0.2mM of each dNTP,
0.5 U of Taq polymerase (Invitrogen) in 16PCR buffer supplied
by the manufacturer and 20 pM each of forward and reverse
primer (Invitrogen). The following primers were used: b-actin
forward primer 59 CGA GGC CCA GAG CAA GAG AG and b-
actin reverse primer 59 CGG TTG GCC TTA GGG TTC AG;
Rae-1 forward primer 59TGA GCT GGA GAT CAG CTA ATG
A and Rae-1 reverse primer 59 GAA GCG GGG AAG TTG
ATG TA; H60 forward primer 59 CAT GGA GCA GTG GAA
GAA CA and H60 reverse primer 59 CAC TCA GAC CCT GGT
TGT CA; Mult1 forward primer 59 CAA TGT CTC TGT CCT
CGG AA and Mult1 reverse primer 59CTG AAC ACG TCT
CAG GCA CT. For qPCR SYBR green master mix (Applied
Biosystem) was used. PCR amplification with the b-actin primers
started with one cycle at 95uC for 10 minutes, then 37 cycles of
95uC for 30 sec, 62uC for 25 sec, and 72uC for 25 sec. Negative
controls included a sample with no DNA substrate. For Rae-1,
H60 and Mult1 primers PCR cycles started with 95uC for
10 minutes, then 32 cycles of 95uC for 30 sec, 55uC for 30 sec,
and 72uC for 30 sec. For determining relative Rae-1 expression,
Rae-1 copy numbers were normalized for b-actin obtained from
standard curves.
Detection of NKG2D L expression by flow cytometry
To stain for NKG2D ligands 2.5610
5 to 5610
5 PyVTu cells,
YAC-1 and RMA cells were treated with anti-CD16/32 (Fc block;
clone 2.4G2; BD Pharmingen) and then stained with the following
antibodies: PE-anti-mouse Rae-1 (pan-specific, clone 186107), PE-
anti-mouse H60 (clone 205326) and Rat IgG2A isotype control-PE
(clone 54447) from R&D, PE-anti-mouse MULT-1 (clone 5D10)
and Armenian hamster IgG isotype control(clone ebio299Arm)
from eBioscience, and PE-anti-mouse MHC class I H-2K
b (clone
AF6-88.5; BD Bioscience) or class I H-2K
k (clone 36-7-5; BD
Bioscience).
NK cell and cd T cell activation assays, intracellular IFNc,
granzyme-B and CD107a/b staining
For in-vitro assays single cell suspensions were prepared from
spleens. Two times 10
6 spleen leukocytes were incubated with 10
5
PyVTu cells for 6 hours in 0.2 ml RPMI containing 10% FCS.
For stimulation 50 ng/ml of PMA (Sigma) and 500 ng/ml of
ionomycin (Sigma) were added after 2 hr of incubation, and
parallel cultures were left unstimulated. For the final 3 hours of the
incubation time 0.2ml of golgi plug (BD Bioscience) and 0.13 mlo f
golgi stop (BD Bioscience) was added to allow accumulation of
intracellular proteins.
For in vivo assays 5610
6 PyVTu cells in HBSS were injected
i.p. into TCR b KO mice, control mice were injected i.p. with
HBSS with no cells. Three days after injection PEC were
harvested from the mice, RBC were removed by lysis and
2610
6 of the PEC were incubated for 4 hours in RPMI/ 10%
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the in vitro assays, for the final 3 hours of the incubation time
0.2ml of golgi plug (BD Bioscience) and 0.13 ml of golgi stop (BD
Bioscience) was added to allow accumulation of intracellular
proteins. The cells tested for in vitro or in vivo activation were
then treated with anti-CD16/32 (Fc block; clone 2.4G2; BD
Pharmingen) and surface stained with FITC-anti-mouse-CD3
(clone- 145-2C11; BD Pharmingen), PerCPCy5.5-anti-mouse
NK.1.1 (clone- PK136; BD Pharmingen), and PE-anti-mouse-cd
TCR (clone-GL3; BD Pharmingen) antibodies for 25 minutes at
room temperature. Cells were then washed and permeabilized
with Cytofix/Cytoperm buffer (BD Biosciences), followed by
staining with PE Cy7-anti-mouse-IFNc (clone XMG1.2; BD
Pharmingen) and APC-anti-human-granzyme-B (clone GB11;
Invitrogen) for 20–25 minutes at room temperature. For CD107
staining both FITC-anti-mouse-CD107a (clone-1D4B; BD Phar-
mingen) and FITC-anti-mouse-CD107b (clone-ABL-93; BD
Pharmingen) antibodies were added along with golgi plug and
golgi stop for four hours and then treated with anti-CD16/32 (Fc
block; clone 2.4G2; BD Pharmingen) and surface stained with
PerCPCy5.5-anti-mouse NK.1.1 (clone PK-136; BD Pharmingen),
PE-anti-mouse-cd TCR (clone GL3; ) for 25 minutes. The cells
were finally analyzed by flow cytometry.
In vitro cytotoxicity assays
Standard 4 h
51Cr release microcytotoxicity assays were used to
determine NK cell activity [48]. Activated PECs or spleen cells of
SCID mice were used as effector cells, in some experiments the NK
cells were enriched by using an NK cell isolation kit (MACS,
Miltenyi Biotech) following the manufacturer’s protocol. The PECs
were activated in vivo by an injection of 4610
6 to 5610
6 PyVTu
cells i.p. two days prior to their harvest.
51Cr-labelled YAC-1 cells,
PyVTu cells or RMA cells were used as targets, and 10
4 target cells
were plated into wells of microtiter plates with varying numbers of
effectors to achieve the planned effector to target (E:T) ratios. After
4 hours of incubation
51Cr release into the supernatants was
measured. The percentage of specific
51Cr release was calculated as
described before [42]. For NKG2D blocking, anti-NKG2D
blocking antibodies (clone CX5; eBioscience or clone MI-6;
eBioscience ) or corresponding isotype controls (Rat IgG1 isotype
HRPN; BioXcell and Rat IgG2a isotype eBioscience) were used at
5mg/ml. For depletion of NK cells anti-NK1.1 antibody (clo-
nePK136; BioXcell ) was injected at the dose of 40 mg/mouse i.p.
one day prior to injection of PyVTu cells.
Supporting Information
Figure S1 NK and cd T cells are activated after i.p. injection of
PyVTu cells but not Rae-1 negative RMA cells. (A) Intracellular
IFNc and granzyme-B staining of NK cells and (B) cd T cells
isolated from the peritoneal cavity of TCRb KO mice that
received i.p. injection of PyVTu1 cells or RMA cells three days
prior their harvest. The cells were tested for IFNc with or without
in vitro PMA and ionomycin stimulation.
Found at: doi:10.1371/journal.ppat.1000924.s001 (1.88 MB TIF)
Figure S2 Activation of NK cells and cd T cells in vivo by i.p.
injection of PyVTu cells or PyV. (A) Left Panel: Increase in
peritoneal NK and cd T cells in response to i.p. injection of PyV
(2610
6 p.f.u.) or PyVTu1 cells (5610
6). PEC harvested from mice
(n=3) 3 days after injection were analyzed individually by flow
cytometry. The numbers show percentages of NK1.1+/CD32 NK
cells and cd TCR+/CD3+ cd T cells, respectively. Right panel:
mean + sd of NK and cd T cell numbers in the PECs of PyV-
infected and PyVTu cell-injected mice in the same experiment. (B)
Intracellular IFNc and (C) granzyme-B staining of cells harvested
from the peritoneal cavity of mice three days after i.p. injection of
PyV or PyVTu cells, gated on NK (upper panels) and cd T cells
(middle panels). IFNc and granzyme-B production was tested with
or without in vitro PMA and ionomycin stimulation. The numbers
indicate IFNc + or granzyme-B + cells, respectively. Bottom panels:
percentages and MFI of IFNc+ and granzyme-B+ NK and cd T
cells. Filled bars represent pooled samples from 2 PyV-infected mice
without stimulation, open bars the means and s.d. of 3 PyVTu-
injected mice without stimulation, the bars with horizontal stripes
pooled samples from 2 PyV-infected mice with stimulation and the
bars with vertical stripes the means and s.d. of 3 PyVTu-injected
mice with stimulation.
Found at: doi:10.1371/journal.ppat.1000924.s002 (1.70 MB TIF)
Figure S3 Acute PyV infection does not induce Rae-1 mRNA
and protein expression in vivo in TCRb KO mice, or in tissue
culture. (A) Relative Rae-1 expression measured by qPCR in the
spleens and salivary glands of naı ¨ve and 7 day PyV- infected
TCRb KO mice and in PyVTu cell lines. N=3 for both naı ¨ve and
infected tissue samples; for tumor cell lines average of PyVTu1,
PyVTu2 and PyVTu3 is shown. (B) Expression of Rae-1 protein in
primary mouse embryonic fibroblast cells, and NIH3T3, UC1B
and MC57G cell lines uninfected or PyV-infected for three days at
a MOI of 1. The open box in each case shows the uninfected
isotype control antibody treated cells, the light shaded grey box
represents the Rae-1-specific antibody- stained uninfected cells
and the dark shaded grey box represents Rae-1 specific antibody-
stained PyV- infected cells.
Found at: doi:10.1371/journal.ppat.1000924.s003 (0.95 MB TIF)
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